March 12, 2025 09:48 AM EDTUpdated 02:21 PM

Insilico nabs $110M Series E for AI drug discovery after stalling Hong Kong IPO plans

Kyle LaHucik

Senior Reporter

Insilico Medicine, part of the first wave of AI-driven drug discovery and development shops, secured a $110 million megaround at a unicorn valuation for its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Insilico nabs $110M Series E for AI drug discovery after stalling Hong Kong IPO plans

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Updated: Zealand partners with Roche on its amylin analog in a deal worth up to $5.3B

Ono licenses rare blood disease drug from Ionis for $280M upfront

Ascletis’ not-so-great weight loss data; Vivace’s $35M Series D

Legend to double Carvykti production as it targets blockbuster status

#CROI25: Merck’s troubled HIV drug heads to regulators; ViiV seeks longer-acting HIV treatment

Obesity drug development—still room to grow

In­sil­i­co nabs $110M Se­ries E for AI drug dis­cov­ery af­ter stalling Hong Kong IPO plans

Senior Reporter

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

Insilico nabs $110M Series E for AI drug discovery after stalling Hong Kong IPO plans